| Dr Michael Raymond Burgess, MD, PHD | |
|
995 Potrero Ave, Building 80, Ward 86, San Francisco, CA 94110-2859 | |
| (415) 206-2407 | |
| Not Available |
| Full Name | Dr Michael Raymond Burgess |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine - Hematology & Oncology |
| Location | 995 Potrero Ave, San Francisco, California |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1083869242 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RH0003X | Internal Medicine - Hematology & Oncology | A106128 (California) | Primary |
| Entity Name | University Of California Sfgh Medical Group |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1326013442 PECOS PAC ID: 5496668410 Enrollment ID: O20040630000226 |
News Archive
Administrators at Howard University Hospital in Washington, D.C., were thrilled to be among the city's first hospitals to get a COVID-19 vaccine, but they knew it could be a tough sell to get staffers to take the shot.
Earlier today, at the American Psychiatric Association Annual Meeting in Philadelphia, Dr. Ian Cook, Principal Investigator and Professor of Psychiatry at UCLA, and a Senior Medical Advisor to NeuroSigma, Inc., presented the results of a Phase Ib open-label clinical trial that studied the effects of eTNS™ on depressive symptoms in Major Depressive Disorder (MDD) as an adjunct to pharmacotherapy. Results from the 17-question Hamilton Depression Rating Scale (HDRS-17), a clinician-rated scale, showed a 50.0% reduction in depression and the Beck Depression Inventory (BDI), a self-reported scale, showed a 58.0% reduction in scores. Both scales achieved statistical significance. In the trial, subjects placed stimulating eTNS™ electrodes on their foreheads for 8 hours each night and their depression was measured every two weeks using recognized standard tests. eTNS was well tolerated and no serious adverse events occurred during the 8-week treatment period.
A multinational study by researchers from the UK, Singapore and Germany has discovered that gene mutations in a protein called titin affect heart function in healthy individuals.
Celldex Therapeutics, Inc. today announced preliminary results from the Company's randomized Phase 2b EMERGE study of CDX-011 (glembatumumab vedotin) antibody drug conjugate in patients with glycoprotein NMB (GPNMB) expressing, advanced, heavily pretreated breast cancer. Preliminary results suggest that CDX-011 induces impressive response rates compared to current, available therapies in patients with advanced, refractory breast cancers with high GPNMB expression.
The Anglo-Dutch food giant Unilever has announced plans to reduce the amount of salt in almost all its 22,000 food products - Unilever says its efforts to establish comprehensive salt reduction targets will help improve public health and are a first worldwide.
› Verified 4 days ago
| Entity Name | City & County Of San Francisco |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1982737524 PECOS PAC ID: 1658280748 Enrollment ID: O20050309000770 |
News Archive
Administrators at Howard University Hospital in Washington, D.C., were thrilled to be among the city's first hospitals to get a COVID-19 vaccine, but they knew it could be a tough sell to get staffers to take the shot.
Earlier today, at the American Psychiatric Association Annual Meeting in Philadelphia, Dr. Ian Cook, Principal Investigator and Professor of Psychiatry at UCLA, and a Senior Medical Advisor to NeuroSigma, Inc., presented the results of a Phase Ib open-label clinical trial that studied the effects of eTNS™ on depressive symptoms in Major Depressive Disorder (MDD) as an adjunct to pharmacotherapy. Results from the 17-question Hamilton Depression Rating Scale (HDRS-17), a clinician-rated scale, showed a 50.0% reduction in depression and the Beck Depression Inventory (BDI), a self-reported scale, showed a 58.0% reduction in scores. Both scales achieved statistical significance. In the trial, subjects placed stimulating eTNS™ electrodes on their foreheads for 8 hours each night and their depression was measured every two weeks using recognized standard tests. eTNS was well tolerated and no serious adverse events occurred during the 8-week treatment period.
A multinational study by researchers from the UK, Singapore and Germany has discovered that gene mutations in a protein called titin affect heart function in healthy individuals.
Celldex Therapeutics, Inc. today announced preliminary results from the Company's randomized Phase 2b EMERGE study of CDX-011 (glembatumumab vedotin) antibody drug conjugate in patients with glycoprotein NMB (GPNMB) expressing, advanced, heavily pretreated breast cancer. Preliminary results suggest that CDX-011 induces impressive response rates compared to current, available therapies in patients with advanced, refractory breast cancers with high GPNMB expression.
The Anglo-Dutch food giant Unilever has announced plans to reduce the amount of salt in almost all its 22,000 food products - Unilever says its efforts to establish comprehensive salt reduction targets will help improve public health and are a first worldwide.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Michael Raymond Burgess, MD, PHD 1500 Owens St, Suite 600, San Francisco, CA 94158-2334 Ph: (415) 839-7127 | Dr Michael Raymond Burgess, MD, PHD 995 Potrero Ave, Building 80, Ward 86, San Francisco, CA 94110-2859 Ph: (415) 206-2407 |
News Archive
Administrators at Howard University Hospital in Washington, D.C., were thrilled to be among the city's first hospitals to get a COVID-19 vaccine, but they knew it could be a tough sell to get staffers to take the shot.
Earlier today, at the American Psychiatric Association Annual Meeting in Philadelphia, Dr. Ian Cook, Principal Investigator and Professor of Psychiatry at UCLA, and a Senior Medical Advisor to NeuroSigma, Inc., presented the results of a Phase Ib open-label clinical trial that studied the effects of eTNS™ on depressive symptoms in Major Depressive Disorder (MDD) as an adjunct to pharmacotherapy. Results from the 17-question Hamilton Depression Rating Scale (HDRS-17), a clinician-rated scale, showed a 50.0% reduction in depression and the Beck Depression Inventory (BDI), a self-reported scale, showed a 58.0% reduction in scores. Both scales achieved statistical significance. In the trial, subjects placed stimulating eTNS™ electrodes on their foreheads for 8 hours each night and their depression was measured every two weeks using recognized standard tests. eTNS was well tolerated and no serious adverse events occurred during the 8-week treatment period.
A multinational study by researchers from the UK, Singapore and Germany has discovered that gene mutations in a protein called titin affect heart function in healthy individuals.
Celldex Therapeutics, Inc. today announced preliminary results from the Company's randomized Phase 2b EMERGE study of CDX-011 (glembatumumab vedotin) antibody drug conjugate in patients with glycoprotein NMB (GPNMB) expressing, advanced, heavily pretreated breast cancer. Preliminary results suggest that CDX-011 induces impressive response rates compared to current, available therapies in patients with advanced, refractory breast cancers with high GPNMB expression.
The Anglo-Dutch food giant Unilever has announced plans to reduce the amount of salt in almost all its 22,000 food products - Unilever says its efforts to establish comprehensive salt reduction targets will help improve public health and are a first worldwide.
› Verified 4 days ago
Dr. Pratyusha Kishore Narra, MBBS Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 3490 California St, San Francisco, CA 94118 Phone: 415-514-6200 Fax: 415-514-6410 | |
Dr. Chelsea Joy Thomsen, M.D., M.S.P.H Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 2 W Portal Ave, San Francisco, CA 94127 Phone: 415-291-0480 | |
Christine Soran, Hematology & Oncology Medicare: Medicare Enrolled Practice Location: 1001 Potrero Ave, Bldg 10, 3rd Floor, Ward 13, Ucsf Division Of General Internal Medicine Sfgh, San Francisco, CA 94110 Phone: 415-206-5164 Fax: 415-206-5586 | |
Stephen Norris Cohen, MD Hematology & Oncology Medicare: Not Enrolled in Medicare Practice Location: 40 Ventura Ave, San Francisco, CA 94116 Phone: 415-681-2171 Fax: 415-681-2171 | |
Mauricio Jalife Bucay, M.D Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 505 Parnassus Ave, San Francisco, CA 94143 Phone: 415-750-4994 Fax: 415-750-8156 | |
Dr. Adriana A.t. Martin, M.D., PH.D. Hematology & Oncology Medicare: Medicare Enrolled Practice Location: 505 Parnassus Ave, San Francisco, CA 94143 Phone: 415-514-7288 | |
Dr. Alexandra Cristina Villasante Fricke, MD Hematology & Oncology Medicare: Medicare Enrolled Practice Location: 655 Montgomery St Ste 810, San Francisco, CA 94111 Phone: 844-847-8216 Fax: 415-520-9150 |